

Scala Biodesign stands at the forefront of the current revolution in protein design, developing software platforms for the efficient and successful engineering of biotherapeutics and enzymes.

Scala's technologies have been applied to dozens of highly challenging proteins across diverse applications and are backed by an unprecedented record of over 130 peer-reviewed publications and collaborations with more than 80 commercial and academic partners. This includes the first-ever one-shot design of a malaria vaccine candidate, now advancing through Phase II clinical trials; enzyme therapies in preclinical studies; therapeutic antibodies in various formats; challenging drug targets; and other proteins previously considered out of reach.

Among Scala's customers are five of the world's top 20 pharmaceutical companies, as well as other market leaders across different verticals. By enabling more efficient optimization of complex biologics, Scala empowers the biopharmaceutical industry to accelerate the development of next-generation therapeutics.